MXPA03011508A - Imidazole derivatives for modulating sodium channels. - Google Patents

Imidazole derivatives for modulating sodium channels.

Info

Publication number
MXPA03011508A
MXPA03011508A MXPA03011508A MXPA03011508A MXPA03011508A MX PA03011508 A MXPA03011508 A MX PA03011508A MX PA03011508 A MXPA03011508 A MX PA03011508A MX PA03011508 A MXPA03011508 A MX PA03011508A MX PA03011508 A MXPA03011508 A MX PA03011508A
Authority
MX
Mexico
Prior art keywords
sodium channels
imidazole derivatives
modulating sodium
alkyl
optionally substituted
Prior art date
Application number
MXPA03011508A
Other languages
Spanish (es)
Inventor
Bigg Dennis
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of MXPA03011508A publication Critical patent/MXPA03011508A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Networks Using Active Elements (AREA)
  • Control Of Transmission Device (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)
  • Detergent Compositions (AREA)

Abstract

The invention relates to compounds of general formula (I) where Rl = an alkyl, cycloalkylalkyl or aralkyl group optionally substituted on the aryl group; R2 = a phenyl group, or R2 = an optionally substituted biphenyl group and R3 = H or alkyl and the pharmaceutically acceptable salts thereof. The above may be used for the production of a medicament for modulating sodium channels and in particular for treatment of pain (for example, neuropathic pain), epilepsy, neurodegenerative conditions and bipolar conditions.
MXPA03011508A 2001-06-14 2002-06-14 Imidazole derivatives for modulating sodium channels. MXPA03011508A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107820A FR2825926A1 (en) 2001-06-14 2001-06-14 Use of new and known imidazole derivatives as sodium channel modulators used for treating e.g. pain, epilepsy, cardiac rhythm disorders, neurodegeneration, depression, irritable bowel syndrome, and diabetic retinopathies
PCT/FR2002/002039 WO2002102375A2 (en) 2001-06-14 2002-06-14 Imidazole derivatives for modulating sodium channels

Publications (1)

Publication Number Publication Date
MXPA03011508A true MXPA03011508A (en) 2004-03-18

Family

ID=8864329

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011508A MXPA03011508A (en) 2001-06-14 2002-06-14 Imidazole derivatives for modulating sodium channels.

Country Status (21)

Country Link
US (3) US7157483B2 (en)
EP (1) EP1401432B1 (en)
JP (1) JP2005500297A (en)
KR (1) KR20040030672A (en)
CN (1) CN1535148A (en)
AT (1) ATE304354T1 (en)
BR (1) BR0210285A (en)
CA (1) CA2449916A1 (en)
CZ (1) CZ297321B6 (en)
DE (1) DE60206171T2 (en)
DK (1) DK1401432T3 (en)
ES (1) ES2249595T3 (en)
FR (1) FR2825926A1 (en)
HU (1) HUP0400195A3 (en)
IS (1) IS2367B (en)
MX (1) MXPA03011508A (en)
NO (1) NO20035553D0 (en)
NZ (1) NZ529741A (en)
PL (1) PL366722A1 (en)
RU (1) RU2296565C2 (en)
WO (1) WO2002102375A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1594847A2 (en) * 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
RU2422450C2 (en) * 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. New phosphorus-containing thymomimetic drugs
EP1898926A2 (en) 2005-05-26 2008-03-19 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
NZ565378A (en) 2005-06-29 2011-03-31 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
WO2007066336A2 (en) * 2005-12-07 2007-06-14 Ramot At Tel Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
AU2006322845A1 (en) * 2005-12-07 2007-06-14 Sepal Pharma Ltd. Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US7883898B2 (en) * 2007-05-07 2011-02-08 General Electric Company Method and apparatus for measuring pH of low alkalinity solutions
US8188080B2 (en) * 2007-10-17 2012-05-29 Sanford-Burnham Medical Research Institute VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
US8815892B2 (en) 2008-03-25 2014-08-26 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
EA022505B1 (en) * 2008-03-25 2016-01-29 Эффектис Фармасьютиклз Аг Novel p2x7r antagonists and their use
KR101602985B1 (en) * 2008-10-06 2016-03-11 시코쿠가세이고교가부시키가이샤 2-benzyl-4-(2,4-dichlorophenyl)-5-methylimidazole compound
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
JP5368244B2 (en) * 2009-10-14 2013-12-18 四国化成工業株式会社 2- (2,4-dichlorobenzyl) -4-aryl-5-methylimidazole compound
JP5368263B2 (en) * 2009-11-04 2013-12-18 四国化成工業株式会社 4- (2,4-dichlorophenyl) -5-methylimidazole compound
JP5368271B2 (en) * 2009-11-20 2013-12-18 四国化成工業株式会社 4- (4-Biphenylyl) -2- (2,4-dichlorobenzyl) imidazole and surface treatment solution
AU2017363206A1 (en) 2016-11-21 2019-06-13 Viking Therapeutics, Inc. Method of treating glycogen storage disease
CA3064940A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
MX2020009843A (en) 2018-03-22 2020-12-11 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound.
WO2024097171A1 (en) * 2022-10-31 2024-05-10 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1046248A (en) * 1962-08-02 1966-10-19 Benger Lab Ltd Substituted imidazoles
US6003118A (en) * 1997-12-16 1999-12-14 Acer Laboratories Inc. Method and apparatus for synchronizing clock distribution of a data processing system
US6414011B1 (en) * 1999-03-26 2002-07-02 Euro-Celtique S.A. Aryl substituted pyrazoles, and pyrroles, and the use thereof
AR024077A1 (en) * 1999-05-25 2002-09-04 Smithkline Beecham Corp ANTIBACTERIAL COMPOUNDS
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
JP4180276B2 (en) * 1999-12-16 2008-11-12 シェーリング コーポレイション Substituted imidazole neuropeptide YY5 receptor antagonist

Also Published As

Publication number Publication date
CN1535148A (en) 2004-10-06
DE60206171D1 (en) 2005-10-20
EP1401432A2 (en) 2004-03-31
FR2825926A1 (en) 2002-12-20
IS2367B (en) 2008-06-15
CZ297321B6 (en) 2006-11-15
RU2004100843A (en) 2005-04-10
WO2002102375A3 (en) 2003-09-25
IS7067A (en) 2003-12-08
NO20035553D0 (en) 2003-12-12
CZ20033550A3 (en) 2005-05-18
JP2005500297A (en) 2005-01-06
EP1401432B1 (en) 2005-09-14
ES2249595T3 (en) 2006-04-01
DE60206171T2 (en) 2006-06-22
HUP0400195A3 (en) 2004-10-28
NZ529741A (en) 2006-10-27
US20040198792A1 (en) 2004-10-07
WO2002102375A2 (en) 2002-12-27
DK1401432T3 (en) 2006-02-06
RU2296565C2 (en) 2007-04-10
BR0210285A (en) 2004-06-29
ATE304354T1 (en) 2005-09-15
PL366722A1 (en) 2005-02-07
US20060069146A1 (en) 2006-03-30
CA2449916A1 (en) 2002-12-27
US7157483B2 (en) 2007-01-02
US20070099975A1 (en) 2007-05-03
US7402602B2 (en) 2008-07-22
HUP0400195A2 (en) 2004-07-28
KR20040030672A (en) 2004-04-09

Similar Documents

Publication Publication Date Title
MXPA03011508A (en) Imidazole derivatives for modulating sodium channels.
JO2646B1 (en) Novel heterocyclic compounds which are active as inhibitors of beta-lactamases
TWI255807B (en) Therapeutic agents
MY140525A (en) Pharmaceutical uses for alpha2delta ligands
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB9801690D0 (en) Therapeutic agents
AU3850600A (en) Dalda analogs and their use
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
PL1685142T3 (en) Phosphinic acid derivatives, beta-secretase inhibitors for the treatment of alzheimer's disease
DE69907419D1 (en) Antitumorwirkstoffe
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
MXPA04005484A (en) Method for preparing echinocandin derivatives.
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
MXPA05006889A (en) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
HRP20050667A2 (en) Corbonyl-amino substituted acyl phenyl urea derivatives, method for the production and use thereof
TW200509921A (en) Alkaline salts
EA200000068A3 (en) New cyano-indole serotonin-reuptake inhibitor compounds, a process for their preparation and pharmaceutical compositions containing them
GEP20063758B (en) Benzothia(Dia)Zine Derivatives and Method for Their Use as AMPA Modulators
AU2002359150A1 (en) Therapeutic heterocycles
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
AU2292199A (en) Adamantanecarboximidamide derivatives and their use as nmda antagonists
WO2003091243A8 (en) Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
MXPA05009122A (en) Substituted benzoylureidopyridyl-piperidine and -pyrrolidine carboxylic acid derivatives, method for the production thereof and the use thereof.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status